retatrutide weight loss results clinical trials trial benefits New Phase 3 data just dropped 👀 Eli Lilly's reported average approaching 30%, with some patients Eli Lilly infiltrates anti-obesity market

We uphold stringent sourcing criteria and depend on peer-reviewed studies and academic research conducted by medical associations and institutions

Low-impact, slow-weighted workouts help your muscles use blood sugar more efficiently, which encourages your body to release more GLP-1

A p-value of less than 0.05 was set as the threshold for clinical significance

In a 48-week phase 2 trial published in The New England Journal of Medicine , adults with obesity (without type 2 diabetes) receiving once-weekly subcutaneous retatrutide at the 12 mg amount achieved a least-squares mean body weight reduction of 24.2%, compared with 2.1% in the placebo group [1]

UCSF Health